

# Total Synthesis of (–)-Nakadomarin A


Simone Bonazzi, Bichu Cheng, Joseph S. Wzorek, and David A. Evans\*

Department of Chemistry and Chemical Biology, Harvard University, Cambridge, Massachusetts 02138, United States

**S** Supporting Information


**ABSTRACT:** The convergent synthesis of the polycyclic alkaloid (–)-nakadomarin A (**1**) is reported. The synthesis plan identified macrocyclic lactam **4** as one of the important synthons (eight steps). The other synthon (five steps) was bicyclo[6.3.0] lactam **5** containing a single stereocenter that controlled all of the subsequent stereochemistry during the assembly process. A silyl triflate-promoted cascade of **4** and **5** was used to assemble the bulk of the alkaloid skeleton with the exception of the C5–C6 bond. The nakadomarin synthesis was then completed in one additional step.

(–)-Nakadomarin A (**1**) is an alkaloid that was isolated in 1997 from the marine sponge *Amphimedon* sp. found off the coast of the Kerama Islands, Okinawa.<sup>1</sup> Biological evaluation of **1** has revealed a wide range of potential therapeutic attributes, including cytotoxic, antimicrobial, and antibacterial activities. While this alkaloid belongs to the manzamine family,<sup>2</sup> it is architecturally distinct. Both its advertised biological properties and structural complexity have highlighted nakadomarin A as an attractive target for synthesis and subsequent drug development research. Accordingly, a number of syntheses and projected routes to this target have been reported.<sup>3</sup> Herein we report a new approach to the synthesis of this structure.



Previous approaches to **1** have relied upon the construction of the 15-membered-ring synthon as a late-stage event. In the present approach, we introduce the 15-membered macrocycle early in the synthesis for reasons to be described. The synthesis plan (Scheme 1) anticipated that nakadomarin A (**1**) might be obtained from bislactam **3** through selective reduction of the six-membered lactam moiety followed by intramolecular alkylation of the iminium ion derived from **2** to form the final C5–C6 bond. We reasoned that **3** could be accessed through a Lewis acid-promoted double conjugate addition of macrocyclic lactam **4** and lactam **5**. This transformation could also be viewed as a formal [4 + 2] cycloaddition. A significant drawback of this plan lay in the lack of an obvious  $\pi$ -facial bias in the reaction of **4** with **5**, which could lead to an undesired diastereomeric adduct.

## Scheme 1. Synthesis Plan for (–)-Nakadomarin A




The decision to proceed with the plan illustrated in Scheme 1 was fortified by the potential interplay of competing C–O transition-state dipole effects that might favor an anti orientation of the dipoles in the formation of **3**. If successful, the stereocenter incorporated into bicyclic lactam **5** could be the singular chiral element in this transformation and might be expected to control the stereochemical outcome of the whole process.

The synthesis of macrocyclic lactam **4** was accomplished in eight steps on a multigram scale (Scheme 2). Commercially available 3-furfural (**6**) was iodinated in 52% yield using the literature procedure.<sup>4</sup> Aldehyde **7** was protected as its dimethyl acetal and directly submitted to Heck coupling with allyl alcohol to afford **8** (69% over two steps).<sup>5</sup> Subsequent Wittig olefination with phosphonium salt **9**<sup>6</sup> followed by acidic isolation incorporated the cis olefin while removing the acetal, affording aldehyde **10** in 89% yield. A Horner–Wadsworth–Emmons Z-olefination reaction with **11** provided methyl ester **12** in 90% yield (*Z/E* >20:1). This ester was then hydrolyzed, and removal of the Boc protecting group followed by cyclization of the product using HBTU gave **4** in 74% yield. The product was recrystallized from MeOH (mp 125–126 °C) and characterized by X-ray analysis.


The synthesis of bicyclic lactam **5** (Scheme 3) featured the use of the Ellman chiral *tert*-butylsulfonamide<sup>7</sup> methodology. Acrolein was condensed with (*R*)-(+)-2-methyl-2-propane-sulfonamide mediated by Ti(OiPr)<sub>4</sub> to provide a 97% yield of chiral imine **13**,<sup>8</sup> which was subjected to Zn-mediated allylation

Received: May 9, 2013

Published: June 10, 2013

Scheme 2. Synthesis of Macrocylic Lactam **4**<sup>a</sup>

<sup>a</sup>Reagents and conditions: (a) *n*-BuLi, morpholine, THF,  $-78\text{ }^{\circ}\text{C}$ , then *s*-BuLi, then  $\text{I}_2$ ; (b)  $\text{CH}(\text{OMe})_3$ , TsOH,  $\text{H}_2\text{O}$ , 3 Å molecular sieves (MS); (c)  $\text{Pd}(\text{OAc})_2$ , allyl alcohol,  $\text{NaHCO}_3$ , DMF,  $50\text{ }^{\circ}\text{C}$ ; (d) KHMDS,  $\text{BocNH}(\text{CH}_2)_5\text{PPh}_3\text{I}$  (**9**),  $-78$  to  $0\text{ }^{\circ}\text{C}$ , then HCl; (e)  $\text{CH}_3\text{O}_2\text{CCH}_2\text{P}(\text{O})(\text{OCH}_2\text{CF}_3)_2$  (**11**), 18-crown-6, KHMDS, THF,  $-78\text{ }^{\circ}\text{C}$ ; (f) NaOH, MeOH,  $\text{H}_2\text{O}$ , rt; (g) TFA, DCM,  $0\text{ }^{\circ}\text{C}$  to rt; (h) *N,N,N',N'*-tetramethyl-*O*-(1*H*-benzotriazol-1-yl)uronium hexafluorophosphate (HBTU),  $\text{NEt}_3$ ,  $\text{CH}_3\text{CN}$ ,  $50\text{ }^{\circ}\text{C}$ .

Scheme 3. Synthesis of Bicyclic Lactam **5**<sup>a</sup>

<sup>a</sup>Reagents and conditions: (a) Zn, LiCl, DMF,  $\text{H}_2\text{O}$  (1 equiv); (b) HCl, MeOH, then NaOH; (c) NaH, **17**, DMF; (d) Grubbs I ( $3 \times 0.5$  mol %), DCM (0.002 M).

following literature precedent.<sup>9</sup> A mixture of **13** and ethyl 2-(bromomethyl)acrylate (**14**)<sup>10</sup> was treated with Zn powder and LiCl in *N,N*-dimethylformamide (DMF) to give the desired chiral amine **15**. In early experiments, the use of excess **14** afforded an *N*-alkylation byproduct. This reaction was circumvented by the addition of 1 equiv of water to the reaction mixture to induce protonation of the Zn(II) amide intermediate. After reaction optimization, **15** was obtained in high yield. The sulfinamide was deprotected under the usual acidic conditions, and  $\alpha$ -methylene- $\gamma$ -lactam **16** was obtained in 86% yield upon exposure to NaOH. Lactam **16** was then *N*-alkylated with 1-iodo-5-hexene (**17**)<sup>11</sup> to give **18**, which was then subjected to ring-closing metathesis to afford **5** in 83% yield.<sup>3e</sup>

With fragments **4** and **5** in hand, we investigated the cascade reaction/cycloaddition, which could be initiated by any number of Lewis acids (Scheme 4). Initial studies were directed to conditions that would facilitate activation of **4** and induce conjugate addition to **5**. With these constraints in mind, we selected *tert*-butyldimethylsilyl triflate (TBSOTf) as a promoter.<sup>12</sup> A 1:1 mixture of **4** and **5** was treated with TBSOTf under a variety of conditions. After a number of attempts, the optimized formation of the polycyclic product **3** was observed. It was found that slow addition of **5** to a solution of **4** activated by TBSOTf in the presence of *iPr*<sub>2</sub>NEt successfully afforded **3** in 79% yield with 9:1 dr (Scheme 4). Optimal results were obtained with 2.0 equiv of freshly distilled TBSOTf and 1.8 equiv of *iPr*<sub>2</sub>NEt [0.3 M in 1,2-dichloroethane (DCE)]. Attempts to catalyze the reaction with TfOH alone failed, suggesting that the

reaction is silyl-catalyzed. The major diastereoisomer **3** was recrystallized, and its structure was determined by X-ray crystallography (Figure 1).





Figure 1. X-ray structures of lactams **3** and **24** (Scheme 4).

Efforts were then directed toward the selective reduction of the six-membered lactam in **3**. Unfortunately, the use of conventional reducing agents (diisobutylaluminum hydride or  $\text{LiAlH}_4$ ) resulted in either complete reduction of the five-membered lactam moiety or a mixture of partial reduction products. Selective reduction of the six-membered lactam was achieved through regioselective alkylation of **3** with  $\text{Me}_3\text{OBF}_4$  followed by  $\text{NaBH}_4$  reduction of the activated amide intermediate **21** (Scheme 4). Semireduction product **2** was recrystallized, and its structure was confirmed by X-ray analysis. It is significant that the use of the slightly more hindered Meerwein salt ( $\text{Et}_3\text{OBF}_4$ ) resulted in significantly reduced reduction selectivity. This implies that steric effects could play some role in the discrimination between the two competing amide carbonyl alkylation events; nevertheless, there appears to be little precedent for these observations. To complete the synthesis, treatment of lactam **2** using modified conditions similar to those reported by Dixon and co-workers<sup>3h</sup> ( $\text{Tf}_2\text{O}$  and 2,6-di-*tert*-butyl-4-methylpyridine) facilitated the rapid formation of intermediate **22**, which was trapped by the furan to afford intermediate **23**. Subsequent reduction using  $\text{NaBH}_3\text{CN}$  afforded (–)-nakadomarin A (**1**) in 52% yield from **3**.

The transformation of bislactam **3** to **1** was then refined to a one-pot procedure. Upon treatment of **3** with  $\text{Tf}_2\text{O}$  and 2,6-di-*tert*-butyl-4-methylpyridine followed by the addition of sodium bis(2-methoxyethoxy)aluminum hydride (Red-Al), both the iminium ion and the six-membered lactam moiety were reduced, affording **1** in 69% yield.


*Cascade diastereoselection.* An attempt to identify the plausible origins of the stereochemical control in the reaction cascade used to merge fragments **4** and **5** was undertaken. While the single stereocenter embedded in **5** provides one of the stereochemical control elements, it was possible that characterization of the minor product diastereomer might reveal other transition-state control elements. Our preconceived idea of the structure of the other possible cascade diastereomer is shown in Scheme 1. After a scale-up of the transformation to give **3** (9:1 dr), we were able to isolate from the product mixture the minor lactam diastereomer **24** (mp 95–97 °C). Its X-ray structure is also

Scheme 4. The Cascade Reaction<sup>a</sup>

<sup>a</sup>Reagents and conditions: (a) 4, TBSOTf, *i*Pr<sub>2</sub>NEt, DCE, rt, then 5, DCE, 14 h; (b) Me<sub>3</sub>OBF<sub>4</sub>, 4 Å MS, DCM, rt, 2 h, then NaBH<sub>4</sub>, MeOH, 0 °C to rt; (c) Tf<sub>2</sub>O, 2,6-di-*tert*-butyl-4-methylpyridine, DCM, rt, 30 min, then NaBH<sub>3</sub>CN, MeOH, rt; (d) Tf<sub>2</sub>O, 2,6-di-*tert*-butyl-4-methylpyridine, DCM, 2 h, then Red-Al, -78 to 60 °C, 3 h.

provided in Figure 1. Compound **24** was unexpectedly derived from the addition of the achiral unsaturated lactam **4** to the more congested concave face of the bicyclic lactam **5**.

**Kinetic selectivity and product stability.** The computed energies (B3LYP/6-31G\*) of the four possible silicon-alkylated product diastereomers **25–28TMS** are provided in Figure 2. The



**Figure 2.** Computed energies (B3LYP/6-31G\*) of silylated vs protonated products.

centrosymmetric trimethylsilyl moiety was used in place of the analogous TBS analogue to simplify the computations. As with any compromise, the relative energies of **25–28TMS** might

under-represent the actual energy differences between **26TBS** and **27TBS**, as the TBS moiety is more sterically demanding than its TMS counterpart. Nevertheless, the energies of these structures substantiate that the most stable silylated structure is **25TMS**, an observation that is consistent with the structure of the major kinetic product diastereomer **3**. It is also evident that **27TMS** is lower in energy than **26TMS**, the minor diastereomer incorrectly projected in Scheme 1. It is evident that both of the isolated product diastereomers (**3** and **24**) have their respective C=O dipoles disposed in an anti orientation, as predicted by the computations.

Calculations for the protonated product diastereomers **25–28H** were also performed for comparison to probe the potential steric effects of the silicon substituent. The stability order of **25–28H** is quite different than that of **25–28TMS**. In this set of structures, **26H** is the most stable diastereomer. Hence, for structures **25–28H**, the computed product energies suggest that C–O dipole effects alone are not a major factor in determining the diastereomer stability and possibly the kinetic selectivities. We thus conclude that the structure of the reaction promoter (TMSOTf or TBSOTf) seems play a role in the observed reaction diastereoselectivity. It also appears that this reaction, first reported by Ihara,<sup>12</sup> could well be a concerted rather than stepwise transformation.

In conclusion, we have reported a convergent synthesis of (–)-nakadomarin A (**1**) from commercially available 3-furfural. The double Michael/cycloaddition reaction facilitates the rapid construction of the target skeleton, while the stereochemical outcome is dictated by the single stereocenter embedded in bicyclic lactam **5**.



## ■ ASSOCIATED CONTENT

## ■ Supporting Information

Experimental procedures and spectroscopic, crystallographic, and computational data. This material is available free of charge via the Internet at <http://pubs.acs.org>.

## ■ AUTHOR INFORMATION

## Corresponding Author

evans@chemistry.harvard.edu

## Notes

The authors declare no competing financial interest.

## ■ ACKNOWLEDGMENTS

Financial support was provided by the National Institutes of Health (Grants GM-33328-24 and GM-081546-04). Fellowships were provided to S.B. by the Stefano Franscini Fund, the Swiss National Science Foundation (PBEZP2-125725), and the Novartis Foundation; B.C. was supported by the Evans–Novartis Fund at Harvard University. We also thank Dr. Shao-Liang Zheng for his help with X-ray data collection and structure determination.

## ■ REFERENCES

(1) (a) Kobayashi, J.; Watanabe, D.; Kawasaki, N.; Tsuda, M. *J. Org. Chem.* **1997**, *62*, 9236. (b) Kobayashi, J.; Tsuda, M.; Ishibashi, M. *Pure Appl. Chem.* **1999**, *71*, 1123.

(2) For the isolation of the related compound manzamine A, see: (a) Sakai, R.; Higa, T. *J. Am. Chem. Soc.* **1986**, *108*, 6404. (b) Magnier, E.; Langlois, Y. *Tetrahedron* **1998**, *54*, 6201. (c) Nakagawa, M. *J. Heterocycl. Chem.* **2000**, *37*, 567. For total syntheses of manzamine A, see: (d) Winkler, J. D.; Axten, J. M. *J. Am. Chem. Soc.* **1998**, *120*, 6425. (e) Martin, S. F.; Humphrey, J. M.; Ali, A.; Hillier, M. C. *J. Am. Chem. Soc.* **1999**, *121*, 866. (f) Humphrey, J. M.; Liao, Y.; Ali, A.; Rein, T.; Wong, Y.-L.; Chen, H.-J.; Courtney, A. K.; Martin, S. F. *J. Am. Chem. Soc.* **2002**, *124*, 8584. (g) Toma, T.; Kita, Y.; Fukuyama, T. *J. Am. Chem. Soc.* **2010**, *132*, 10233. (h) Jakubec, P.; Hawkins, A.; Felzmann, W.; Dixon, D. J. *J. Am. Chem. Soc.* **2012**, *134*, 17482–17485. For a biosynthesis of manzamine A, see: (i) Baldwin, J. E.; Whitehead, R. C. *Tetrahedron Lett.* **1992**, *33*, 2059.

(3) For total syntheses of nakadomarin A, see: (a) Nagata, T.; Nakagawa, M.; Nishida, A. *J. Am. Chem. Soc.* **2003**, *125*, 7484. (b) Ono, K.; Nakagawa, M.; Nishida, A. *Angew. Chem.* **2004**, *116*, 2054. (c) Young, I. S.; Kerr, M. A. *J. Am. Chem. Soc.* **2007**, *129*, 1465. (d) Jakubec, P.; Cockfield, D. M.; Dixon, D. J. *J. Am. Chem. Soc.* **2009**, *131*, 16632. (e) Nilson, M. G.; Funk, R. L. *Org. Lett.* **2010**, *12*, 4912. (f) Kyle, A. F.; Jakubec, P.; Cockfield, D. M.; Cleator, E.; Skidmore, J.; Dixon, D. J. *Chem. Commun.* **2011**, *47*, 10037. (g) Cheng, B.; Wu, F.; Yang, X.; Zhou, Y.; Wan, X.; Zhai, H. *Chem.—Eur. J.* **2011**, *17*, 12569. (h) Jakubec, P.; Kyle, A. F.; Calleja, J.; Dixon, D. J. *Tetrahedron Lett.* **2011**, *52*, 6094. (i) Yu, M.; Wang, C.; Kyle, A. F.; Jakubec, P.; Dixon, D. J.; Schrock, R. R.; Hoveyda, A. H. *Nature* **2011**, *479*, 88. For a formal synthesis of nakadomarin A, see: (j) Stockman, R. A.; McDermott, P. J.; Newton, A. F.; Magnus, P. *Synlett* **2010**, 559. (k) Inagaki, F.; Kinebuchi, M.; Miyakoshi, N.; Mukai, C. *Org. Lett.* **2010**, *12*, 1800. For synthetic studies toward (–)-nakadomarin A, see: (l) Fürstner, A.; Guth, O.; Rumbo, A.; Seidel, G. *J. Am. Chem. Soc.* **1999**, *121*, 11108. (m) Fürstner, A.; Guth, O.; Düffels, A.; Seidel, G.; Liebl, M.; Gabor, B.; Mynott, R. *Chem.—Eur. J.* **2001**, *7*, 4811. (n) Nagata, T.; Nishida, A.; Nakagawa, M. *Tetrahedron Lett.* **2001**, *42*, 8345. (o) Magnus, P.; Fielding, M. R.; Wells, C.; Lynch, V. *Tetrahedron Lett.* **2002**, *43*, 947. (p) Leclerc, E.; Tius, M. A. *Org. Lett.* **2003**, *5*, 1171. (q) Ahrendt, K. A.; Williams, R. M. *Org. Lett.* **2004**, *6*, 4539. (r) Young, I. S.; Williams, J. L.; Kerr, M. A. *Org. Lett.* **2005**, *7*, 953. (s) Nilson, M. G.; Funk, R. L. *Org. Lett.* **2006**, *8*, 3833. (t) Deng, H.; Yang, X.; Tong, Z.; Li, Z.; Zhai, H. *Org. Lett.* **2008**, *10*, 1791. (u) Haimowitz, T.; Fitzgerald, M. E.; Winkler, J. D. *Tetrahedron Lett.* **2011**, *52*, 2162.

(4) Lee, G. C. M.; Holmes, J. M.; Harcourt, D. A.; Garst, M. E. *J. Org. Chem.* **1992**, *57*, 3126.

(5) Jeffery, T. *Tetrahedron Lett.* **1991**, *32*, 2121.

(6) (a) Mattingly, P. G. *Synthesis* **1990**, 366. (b) Nantermet, P. G.; Barrow, J. C.; Lindsley, S. R.; Young, M. B.; Mao, S. S.; Carroll, S.; Bailey, C.; Bosserman, M.; Colussi, D.; McMasters, D. R.; Vacca, J. P.; Selnick, H. G. *Bioorg. Med. Chem. Lett.* **2004**, *14*, 2141.

(7) (a) Liu, G.; Cogan, D. A.; Ellman, J. A. *J. Am. Chem. Soc.* **1997**, *119*, 9913. (b) Ellman, J. A. *Pure Appl. Chem.* **2003**, *75*, 39. (c) Ellman, J. A.; Owens, T. D.; Tang, T. P. *Acc. Chem. Res.* **2002**, *35*, 984.

(8) (a) Raghavan, S.; Krishnaiah, V.; Sridhar, B. *J. Org. Chem.* **2010**, *75*, 498. (b) Liu, G.; Cogan, D. A.; Owens, T. D.; Tang, T. P.; Ellman, J. A. *J. Org. Chem.* **1999**, *64*, 1278.

(9) Shen, A.; Liu, M.; Jia, Z.-S.; Xu, M.-H.; Lin, G.-Q. *Org. Lett.* **2010**, *12*, 5154.

(10) **14** is commercially available from Sigma-Aldrich (CAS no. 17435-72-2). It can also be prepared in two steps from ethyl acrylate. See: (a) Yu, C.; Liu, B.; Hu, L. *J. Org. Chem.* **2001**, *66*, 5413. (b) Villieras, J.; Rambaud, M. *Synthesis* **1982**, 924.

(11) Baldwin, J. E.; Bischoff, L.; Claridge, T. D. W.; Heupel, F. A.; Spring, D. R.; Whitehead, R. C. *Tetrahedron* **1997**, *53*, 2271.

(12) (a) Takasu, K.; Nishida, N.; Ihara, M. *Tetrahedron Lett.* **2003**, *44*, 7429. (b) Takasu, K.; Nishida, N.; Tomimura, A.; Ihara, M. *J. Org. Chem.* **2005**, *70*, 3957. (c) Ihara, M.; Takino, Y.; Tomotake, M.; Fukumoto, K. *J. Chem. Soc., Perkin Trans. 1* **1990**, 2287. (d) Ihara, M.; Kirihara, T.; Kawaguchi, A.; Tsuruta, M.; Fukumoto, K.; Kametan, T. *J. Chem. Soc., Perkin Trans. 1* **1987**, 1719. (e) Takasu, K.; Nishida, N.; Ihara, M. *Synthesis* **2004**, 2222.